高级检索
当前位置: 首页 > 详情页

Aberrant CircTMEM45A Facilitates Inflammatory Progression of Esophageal Squamous Cell Carcinoma through m5C-Mediated NLRP3 Activation

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 自然指数

机构: [1]Department of Tumor lmmunotherapy, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050035, China [2]Research Center and Tumor Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050017, China [3]The Third Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050011, China [4]Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer. Shiiiazhuang.050011.China
出处:
ISSN:

摘要:
The lack of diagnostic and therapeutic targets precludes effective treatment of esophageal cancer, rooted in the limited mechanistic understanding of cancer initiation and progression. Non-mutational epigenetic reprogramming, including altered 5-methylcytosine (m5C) modification and circular RNA (circRNA) expression, can drive tumorigenesis and impact cancer biology. Herein, we identified upregulation of the circRNA hsa_circ_0066658 (termed as circTMEM45A) in esophageal squamous cell carcinoma (ESCC) tissues, which was correlated with advanced clinical stages and poor survival. Functionally, elevated circTMEM45A facilitated ESCC malignant progression both in vitro and in vivo. Mechanistically, circTMEM45A interacted with the methyltransferase NSUN2 and m5C readers ALYREF and YBX1, promoting the nuclear export and stability of NLRP3 mRNA to activate the NLRP3/caspase 1/IL-1β inflammatory pathway. Additionally, circTMEM45A stabilized IL1B mRNA by binding to U2AF2 and stabilized IL1R1 mRNA by serving as a protein scaffold to enhance the IGF2BP2/HUR interaction, further activating the IL-1β/IL1R1 pro-inflammatory cascade in the tumor microenvironment. These findings reveal crosstalk between circRNA and m5C modification that drives inflammatory progression, highlighting circTMEM45A as a potential diagnostic and therapeutic target in ESCC.

基金:
语种:
PubmedID:
中科院分区:
出版当年[2025]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Tumor lmmunotherapy, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050035, China [2]Research Center and Tumor Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang,Hebei 050017, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号